TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
Drug
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease...
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III...
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center,...
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical...
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...
NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings
The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...
Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...
Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...
GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...